{"id":12693,"date":"2025-12-15T12:16:54","date_gmt":"2025-12-15T11:16:54","guid":{"rendered":"https:\/\/www.id-solutions.fr\/?p=12693"},"modified":"2026-02-25T10:05:29","modified_gmt":"2026-02-25T09:05:29","slug":"press-release-id-solutions-oncobit","status":"publish","type":"post","link":"https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/","title":{"rendered":"Press release <br>ID SOLUTIONS &#038; ONCOBIT"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>ID SOLUTIONS and Oncobit join forces<\/strong><\/h2>\n\n\n\n<div class=\"wp-block-columns is-not-stacked-on-mobile is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-gallery has-nested-images columns-2 is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex\">\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"423\" height=\"369\" data-id=\"12731\" src=\"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/12\/logo_ids-1.png\" alt=\"\" class=\"wp-image-12731\" srcset=\"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/12\/logo_ids-1.png 423w, https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/12\/logo_ids-1-300x262.png 300w\" sizes=\"(max-width: 423px) 100vw, 423px\" \/><\/figure>\n<\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\"><div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large\"><img decoding=\"async\" width=\"1024\" height=\"244\" src=\"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/12\/Logo-Oncobit-1-1024x244.png\" alt=\"\" class=\"wp-image-12732\" srcset=\"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/12\/Logo-Oncobit-1-1024x244.png 1024w, https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/12\/Logo-Oncobit-1-300x72.png 300w, https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/12\/Logo-Oncobit-1-768x183.png 768w, https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/12\/Logo-Oncobit-1.png 1241w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<p><strong>Montpellier, France, and Zurich, Switzerland \u2013 December 2025<\/strong><\/p>\n\n\n\n<p>ID Solutions and Oncobit AG announce a strategic partnership.They aim to speed up the development and rollout of new tests.These tests quickly detect cancer biomarkers from a simple blood sample. This collaboration strengthens both companies\u2019 commitment to advancing precision oncology.<\/p>\n\n\n\n<p>The partnership brings together the complementary expertise of two leaders in their respective fields:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ID Solutions<\/strong>, a French expert in developing digital PCR\u2013based tests, leveraging technology capable of detecting extremely low quantities of tumor DNA, crucial for modern oncology applications.<\/li>\n\n\n\n<li>Oncobit is a Swiss company known for monitoring assays and analytical software. It helps clinicians interpret results and track disease progression during the patient journey.<\/li>\n<\/ul>\n\n\n\n<p>Together, the two companies will develop new and easy-to-use oncology tests. These tests will help clinicians make faster and more personalized treatment decisions. All tests developed under this partnership will comply with IVDR (In Vitro Diagnostic Regulation), meeting European regulatory requirements for clinical diagnostic use.<br><br>In practice, this partnership will:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Deliver results in under 24 hours to identify key genetic biomarkers used in targeted cancer therapies, helping physicians rapidly select the most appropriate treatment;<\/li>\n\n\n\n<li>Enable treatment monitoring by quantifying tumor-derived biomarkers in the blood, allowing for more precise and timely therapeutic adjustments.<\/li>\n<\/ul>\n\n\n\n<p>The patented technologies of ID Solutions and Oncobit provide a strong base for highly sensitive oncology diagnostics. These tests are reliable. They can be used in major hospitals and decentralized laboratories. This paves the way for cancer care that is faster, more personalized, and more accessible.<\/p>\n\n\n\n<p><em>\u201c By<\/em> <em>partnering with Oncobit, we are taking a major step toward bringing digital PCR into clinical oncology diagnostics and patient monitoring,<\/em>\u201d said Lise Grewis, President of ID Solutions. \u201c<em>Being able to detect cancer biomarkers in less than 24 hours and follow disease evolution in real time provides clinicians with a new way to support their patients more rapidly and more precisely.<\/em>\u201d<\/p>\n\n\n\n<p>\u201c<em>This partnership reflects our shared vision of making personalized oncology care accessible worldwide,<\/em>\u201d added Dr. Claudia Scheckel, CEO of Oncobit AG. \u201c<em>By combining our complementary expertise, we are equipping clinicians with precision tools that set new standards in sensitivity, reliability, and patient monitoring.<\/em>\u201d<\/p>\n\n\n\n<p>This collaboration represents a significant advancement in the fight against cancer. By using new technology, clinical expertise, and strong industry standards, ID Solutions and Oncobit are advancing oncology diagnostics.They are helping create a new era in cancer testing. These tests deliver accurate, real-time results and keep patients at the center.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>About ID Solutions<\/strong><\/h3>\n\n\n\n<p><strong>ID Solutions<\/strong> is a French company based in <strong>Montpellier<\/strong>, specialising in the development of innovative diagnostic solutions in oncology. ID Solutions is a leader in liquid biopsy and digital PCR. It develops tools that detect and monitor cancer from a simple blood sample. These tools provide highly reliable results. The company is known for its ability to validate and control the entire analytical process. This guarantees fast, accurate and standardised results for clinicians and patients.<\/p>\n\n\n\n<p>For further informations: <a href=\"https:\/\/www.id-solutions.fr\/en\/\">www.id-solutions.fr\/en<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>About Oncobit<\/strong><\/h3>\n\n\n\n<p>Oncobit is a leading Swiss company in precision oncology. It has developed a scalable cancer-monitoring platform. It is based on highly sensitive detection of tumor biomarkers in blood samples. Its cloud-based analytical software, trained on data from both patients and healthy individuals, ensures robust and standardized reporting. Oncobit\u2019s solutions are used by an increasing number of clinical laboratories, hospitals, and pharmaceutical partners.<\/p>\n\n\n\n<p>For further informations: <a href=\"https:\/\/oncobit.com\/en\/\">https:\/\/oncobit.com\/en\/<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ID SOLUTIONS and Oncobit join forces to make cancer diagnosis and monitoring faster and more personalised thanks to digital PCR.<\/p>\n","protected":false},"author":8,"featured_media":12707,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","footnotes":""},"categories":[120],"tags":[],"class_list":["post-12693","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnership"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Press release ID SOLUTIONS &amp; ONCOBIT | ID SOLUTIONS<\/title>\n<meta name=\"description\" content=\"ID SOLUTIONS and Oncobit join forces to make cancer diagnosis and monitoring faster and more personalised thanks to digital PCR.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Press release ID SOLUTIONS &amp; ONCOBIT | ID SOLUTIONS\" \/>\n<meta property=\"og:description\" content=\"ID SOLUTIONS and Oncobit join forces to make cancer diagnosis and monitoring faster and more personalised thanks to digital PCR.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/\" \/>\n<meta property=\"og:site_name\" content=\"ID SOLUTIONS\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-15T11:16:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-25T09:05:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/12\/LK-ONCOBIT.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1890\" \/>\n\t<meta property=\"og:image:height\" content=\"1417\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Joris Calmette\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Joris Calmette\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Press release ID SOLUTIONS & ONCOBIT | ID SOLUTIONS","description":"ID SOLUTIONS and Oncobit join forces to make cancer diagnosis and monitoring faster and more personalised thanks to digital PCR.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/","og_locale":"en_US","og_type":"article","og_title":"Press release ID SOLUTIONS & ONCOBIT | ID SOLUTIONS","og_description":"ID SOLUTIONS and Oncobit join forces to make cancer diagnosis and monitoring faster and more personalised thanks to digital PCR.","og_url":"https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/","og_site_name":"ID SOLUTIONS","article_published_time":"2025-12-15T11:16:54+00:00","article_modified_time":"2026-02-25T09:05:29+00:00","og_image":[{"width":1890,"height":1417,"url":"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/12\/LK-ONCOBIT.jpg","type":"image\/jpeg"}],"author":"Joris Calmette","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Joris Calmette","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/#article","isPartOf":{"@id":"https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/"},"author":{"name":"Joris Calmette","@id":"https:\/\/www.id-solutions.fr\/en\/#\/schema\/person\/77f1a457d9d1958a66574ae901e93acc"},"headline":"Press release ID SOLUTIONS &#038; ONCOBIT","datePublished":"2025-12-15T11:16:54+00:00","dateModified":"2026-02-25T09:05:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/"},"wordCount":573,"publisher":{"@id":"https:\/\/www.id-solutions.fr\/en\/#organization"},"image":{"@id":"https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/12\/LK-ONCOBIT.jpg","articleSection":["Partnership"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/","url":"https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/","name":"Press release ID SOLUTIONS & ONCOBIT | ID SOLUTIONS","isPartOf":{"@id":"https:\/\/www.id-solutions.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/#primaryimage"},"image":{"@id":"https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/12\/LK-ONCOBIT.jpg","datePublished":"2025-12-15T11:16:54+00:00","dateModified":"2026-02-25T09:05:29+00:00","description":"ID SOLUTIONS and Oncobit join forces to make cancer diagnosis and monitoring faster and more personalised thanks to digital PCR.","breadcrumb":{"@id":"https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/#primaryimage","url":"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/12\/LK-ONCOBIT.jpg","contentUrl":"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/12\/LK-ONCOBIT.jpg","width":1890,"height":1417},{"@type":"BreadcrumbList","@id":"https:\/\/www.id-solutions.fr\/en\/2025\/12\/15\/press-release-id-solutions-oncobit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.id-solutions.fr\/en\/home\/"},{"@type":"ListItem","position":2,"name":"Press release ID SOLUTIONS &#038; ONCOBIT"}]},{"@type":"WebSite","@id":"https:\/\/www.id-solutions.fr\/en\/#website","url":"https:\/\/www.id-solutions.fr\/en\/","name":"ID SOLUTIONS","description":"Le diagnostic de pr\u00e9cision au c\u0153ur de notre ADN","publisher":{"@id":"https:\/\/www.id-solutions.fr\/en\/#organization"},"alternateName":"ID SOLUTIONS","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.id-solutions.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.id-solutions.fr\/en\/#organization","name":"ID SOLUTIONS","alternateName":"ID SOLUTIONS","url":"https:\/\/www.id-solutions.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.id-solutions.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/01\/logo-ids.png","contentUrl":"https:\/\/www.id-solutions.fr\/wp-content\/uploads\/2025\/01\/logo-ids.png","width":423,"height":369,"caption":"ID SOLUTIONS"},"image":{"@id":"https:\/\/www.id-solutions.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/id-solutions-diagnostic"]},{"@type":"Person","@id":"https:\/\/www.id-solutions.fr\/en\/#\/schema\/person\/77f1a457d9d1958a66574ae901e93acc","name":"Joris Calmette","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/1c15e900c73c13ce84a6aef94036aee729f5f41ecaa8bb3b47fc358ff626c5fb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1c15e900c73c13ce84a6aef94036aee729f5f41ecaa8bb3b47fc358ff626c5fb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1c15e900c73c13ce84a6aef94036aee729f5f41ecaa8bb3b47fc358ff626c5fb?s=96&d=mm&r=g","caption":"Joris Calmette"}}]}},"_links":{"self":[{"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/posts\/12693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/comments?post=12693"}],"version-history":[{"count":16,"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/posts\/12693\/revisions"}],"predecessor-version":[{"id":13219,"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/posts\/12693\/revisions\/13219"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/media\/12707"}],"wp:attachment":[{"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/media?parent=12693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/categories?post=12693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.id-solutions.fr\/en\/wp-json\/wp\/v2\/tags?post=12693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}